Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365209 · ClinicalTrials.gov registry record · Phase 2
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00365209: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00365209 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00365209, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Curcumin is a compound found in plants that may prevent colon cancer from forming. This phase II trial is studying how well curcumin works in preventing colon cancer in smokers with aberrant crypt foci.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG curcumin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365209
The ClinicalTrials.gov registry entry for NCT00365209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00365209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00365209 about?
NCT00365209 is a clinical study titled "Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)". Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Curcumin is a compound found in plants that may prevent colon cancer from forming. This phase II trial is studying how well curcumin works in preventing colon cancer in smokers with aberrant crypt ...
What is the current status of trial NCT00365209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2006-10. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00365209?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), curcumin (DRUG).
Who is sponsoring clinical trial NCT00365209?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.